China Resources Double-Crane Pharmaceutical Co Ltd Relative Valuation - China Resources Double-Crane Pharmaceutical Co Ltd

Watchlist Manager

Watchlist

Price: 18.89 CNY 0.53% Market Closed

Market Cap: ¥19.6B

C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	CN

Multiples-Based Value

The Multiples-Based Value for China Resources Double-Crane Pharmaceutical Co Ltd (600062) under the Base Case is 21.75 CNY. Compared with the current market price of 18.89 CNY, the stock appears Undervalued by 13%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is relative valuation?

How is Multiples-Based Value calculated?

Multiples-Based Value

Base Case

Undervaluation 13%

Multiples-Based Value

Price ¥18.89

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
CN	C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	19.6B CNY	1.8	12.4	11	11
US		Eli Lilly and Co NYSE:LLY	883.9B USD	13.6	42.8	28.9	30.8
US		Johnson & Johnson NYSE:JNJ	585.2B USD	6.2	21.8	15.2	18.6
UK		AstraZeneca PLC LSE:AZN	237.5B GBP	5.4	31.2	17.2	24.2
CH		Roche Holding AG SIX:ROG	248.4B CHF	4.1	19.7	11.6	13.1
US		Merck & Co Inc NYSE:MRK	299.1B USD	4.6	16.4	10.1	12.3
CH		Novartis AG SIX:NOVN	236.4B CHF	5.4	21.8	13.5	17.3
IE	E	Endo International PLC LSE:0Y5F	237.1B USD	102.3	-81.1	375.3	941.3
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.3	7.6	9
US		Pfizer Inc NYSE:PFE	161B USD	2.6	20.7	7.9	10.5
US		Bristol-Myers Squibb Co NYSE:BMY	120B USD	2.5	17	7.2	8.8

				Revenue Growth	P/S to Growth
CN	C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	Average P/S: 13.8 1.8	3%	0.6
US		Eli Lilly and Co NYSE:LLY	13.6	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6.2	7%	0.9
UK		AstraZeneca PLC LSE:AZN	5.4	N/A	N/A
CH		Roche Holding AG SIX:ROG	4.1	4%	1
US		Merck & Co Inc NYSE:MRK	4.6	5%	0.9
CH		Novartis AG SIX:NOVN	5.4	5%	1.1
IE	E	Endo International PLC LSE:0Y5F	102.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	1%	3.4
US		Pfizer Inc NYSE:PFE	2.6	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.5	-5%	N/A

				Earnings Growth	PEG
CN	C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	Average P/E: 21.4 12.4	8%	1.6
US		Eli Lilly and Co NYSE:LLY	42.8	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.8	7%	3.1
UK		AstraZeneca PLC LSE:AZN	31.2	26%	1.2
CH		Roche Holding AG SIX:ROG	19.7	14%	1.4
US		Merck & Co Inc NYSE:MRK	16.4	14%	1.2
CH		Novartis AG SIX:NOVN	21.8	14%	1.6
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -81.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.3	1%	10.3
US		Pfizer Inc NYSE:PFE	20.7	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	17	16%	1.1

				EBITDA Growth	EV/EBITDA to Growth
CN	C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	Average EV/EBITDA: 46 11	20%	0.5
US		Eli Lilly and Co NYSE:LLY	28.9	22%	1.3
US		Johnson & Johnson NYSE:JNJ	15.2	2%	7.6
UK		AstraZeneca PLC LSE:AZN	17.2	13%	1.3
CH		Roche Holding AG SIX:ROG	11.6	6%	1.9
US		Merck & Co Inc NYSE:MRK	10.1	3%	3.4
CH		Novartis AG SIX:NOVN	13.5	5%	2.7
IE	E	Endo International PLC LSE:0Y5F	375.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.6	1%	7.6
US		Pfizer Inc NYSE:PFE	7.9	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.2	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
CN	C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	Average EV/EBIT: 99.7 11	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	30.8	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.6	6%	3.1
UK		AstraZeneca PLC LSE:AZN	24.2	21%	1.2
CH		Roche Holding AG SIX:ROG	13.1	6%	2.2
US		Merck & Co Inc NYSE:MRK	12.3	6%	2.1
CH		Novartis AG SIX:NOVN	17.3	9%	1.9
IE	E	Endo International PLC LSE:0Y5F	941.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9	2%	4.5
US		Pfizer Inc NYSE:PFE	10.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.8	-7%	N/A

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

Competitors Multiples
China Resources Double-Crane Pharmaceutical Co Ltd Competitors

See Also

Company

Help

Tools

Stocks

China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

Competitors Multiples China Resources Double-Crane Pharmaceutical Co Ltd Competitors

See Also

Company

Help

Tools

Stocks

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Competitors Multiples
China Resources Double-Crane Pharmaceutical Co Ltd Competitors